Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Neuropeptide Y (NPY)
Also known as: NPY, Pro-neuropeptide Y
Two completed human clinical trials, both intranasal, both targeting psychiatric endpoints nobody expected from a hunger peptide. Neuropeptide Y (NPY) is a 36-amino-acid signaling molecule and the most abundant neuropeptide in the mammalian brain. It operates through five receptor subtypes (Y1 through Y5), each triggering distinct effects. The appetite stimulation data comes entirely from rodent intracerebroventricular infusion; no human has shown orexigenic effects from peripheral dosing. What did translate to humans: dose-dependent anxiolytic activity at 4.6 to 9.6 mg intranasal in a PTSD dose-ranging trial (NCT01533519, PMC5795352). The barrier is access. Lab-grade NPY runs $337 to $537 per milligram, and it doesn't exist on the gray market.
What Is Neuropeptide Y (NPY)?
Two psychiatric trials. Zero appetite trials in humans. That gap tells you everything about where NPY research actually stands. Neuropeptide Y is a 36-amino-acid, C-terminally amidated peptide first isolated from porcine brain by Tatemoto in 1982. It belongs to the pancreatic polypeptide family alongside peptide YY and pancreatic polypeptide.
The "most potent orexigenic peptide in the brain" label comes from decades of rodent studies using intracerebroventricular (ICV) infusion, a route that delivers NPY directly into brain ventricles. Inject it centrally in a rat, and feeding behavior starts within minutes. But NPY does not cross the blood-brain barrier after subcutaneous injection. That single pharmacokinetic fact eliminates peripheral dosing as a path to appetite or anxiety endpoints.
What does work in humans is intranasal delivery. The PTSD dose-ranging trial (NCT01533519) tested five escalating doses from 1.4 to 9.6 mg through an olfactory-targeted device. Anxiolytic signal appeared above 4.6 mg, with BAI scores dropping roughly 2 points per milligram increase (PMC5795352). A separate MDD trial showed MADRS score improvement at 5 hours (Cohen's d = 0.61) and 24 hours (d = 0.67) after a single 6.8 mg dose. The effect faded by 48 hours.
NPY signals through Y1, Y2, Y4, Y5, and Y6 G-protein-coupled receptors. The anxiolytic arm runs through Y1 receptors in the amygdala. The appetite arm runs through Y1 and Y5 receptors in the hypothalamus. Military studies correlated high plasma NPY with stress resilience in Special Forces trainees [1]. The molecule is real. The access problem is also real: $337 to $537 per milligram as a lab reagent, no consumer market, no compounding pathway.
How Neuropeptide Y (NPY) Works
NPY signals through five G-protein-coupled receptors (Y1, Y2, Y4, Y5, Y6) that couple to inhibitory Gi/Go proteins. Receptor activation suppresses adenylyl cyclase, drops intracellular cyclic AMP, and modulates calcium and potassium channel conductance to shift neuronal excitability.
The appetite pathway starts in the arcuate nucleus. Low leptin and high ghrelin activate NPY neurons during energy deficit. Released NPY binds Y1 and Y5 receptors on downstream neurons in the paraventricular nucleus. This drives orexigenic signaling while simultaneously shutting down anorexigenic POMC/CART neurons through Y1-mediated GABA release. The Y2 receptor sits presynaptically on NPY terminals, providing negative feedback to cap further release.
The anxiety arm is anatomically separate. In the amygdala, Y1 receptor activation dampens CRF (corticotropin-releasing factor) signaling. This reduces amygdalar excitability, producing the anxiolytic effects confirmed in the NCT01533519 intranasal trial. Military stress resilience data aligns with this pathway; soldiers with higher endogenous NPY showed better performance under extreme conditions [1].
Peripherally, NPY is co-stored and co-released with norepinephrine from sympathetic nerve terminals. Postjunctional Y1 receptors on vascular smooth muscle potentiate norepinephrine-mediated vasoconstriction. This is the main peripheral effect of subcutaneous administration and the reason blood pressure monitoring is non-negotiable.
In bone, hypothalamic Y2 receptor signaling modulates sympathetic output to osteoblasts. Local Y1 activation on osteoblasts directly promotes bone formation.
Neuropeptide Y (NPY) Benefits
- Neuropeptide Y benefits center on anxiolytic activity, stress resilience, and appetite regulation research.
- Dose-dependent anxiety reduction in humans. The PTSD trial (NCT01533519) tracked BAI score drops of roughly 2 points per milligram increase above 4.6 mg intranasal (PMC5795352). That is one of very few peptides with replicated anxiolytic signal in a controlled human trial.
- Stress resilience correlation in military populations. In a US Army survival-school study, higher plasma NPY tracked better performance under stress, and Special Forces soldiers ran higher levels than other soldiers [1].
- The strongest orexigenic signal of any known peptide in rodent ICV models. Central NPY infusion triggers immediate, dose-dependent feeding behavior. Chronic infusion produces sustained weight gain and metabolic shifts toward lipogenesis.
- Single-dose antidepressant signal. A 6.8 mg intranasal dose improved MADRS depression scores at 5 hours (Cohen's d = 0.61) and 24 hours (d = 0.67) in the MDD pilot trial. Effect disappeared by 48 hours, suggesting repeated dosing would be required.
- Neuroprotective properties under ischemic and excitotoxic conditions in preclinical models, with Y1 receptor-mediated suppression of excitatory neurotransmission as the proposed mechanism.
- Bone formation promotion through Y2 receptor signaling in the hypothalamus and direct Y1 activation on osteoblasts, documented in long-term animal studies.
Neuropeptide Y (NPY): Science vs Community Consensus
Intranasal NPY shows dose-dependent anxiolytic and antidepressant effects in two completed human trials.
Read the evidence (key study, limitations)
Appetite stimulation is well-documented in rodent ICV models only, not in humans via peripheral routes. No subcutaneous human dosing data exists.
NCT01533519: PTSD dose-ranging trial; 5 escalating intranasal doses (1.4–9.6 mg); dose-dependent anxiolytic effect with signal above 4.6 mg; BAI score reduced ~2 points per 1 mg increase (IJNP 2018, PMC5795352)
All human data is intranasal only. NPY does not cross the BBB after peripheral SC injection. No approved indication. Not on FDA 503A/B bulks lists: no US compounding pathway. MDD trial (IJNP 2020) effect lasted only 24h, suggesting need for repeated dosing not yet characterized.
No established community self-administration protocol.
Read the reports (common issues 4)
NPY does not appear in the gray-market research peptide market. Theoretical interest in appetite stimulation and stress resilience derived from literature: no documented personal protocols.
- Extremely high cost: ~$337–537/mg (lab reagent only; ~$2,300+ per clinical dose)
- Not found in any consumer-grade peptide listing checked
- No practical intranasal delivery method available for self-administration (requires specialized olfactory-targeted device)
- SC injection does not produce CNS effects: poor BBB penetration means appetite and anxiety endpoints are not reachable via subcutaneous route
Two completed human clinical trials exist (intranasal, mg-range doses) but community self-administration is essentially nonexistent. NPY is absent from the gray market. The compound exists at the intersection of research laboratory and clinic only.
Neuropeptide Y (NPY) Dosage Guide
Start with the most important practical point: subcutaneous NPY will not produce appetite or anxiety effects. Those endpoints require intranasal delivery through an olfactory-targeted device, not a standard nasal spray bottle. The clinical trials used a custom OptiNose-type device.
Reconstitution math for SC research use: a 2 mg vial reconstituted with 2 mL bacteriostatic water gives 1 mg/mL (1000 mcg/mL). At the beginner dose of 50 mcg, that's 5 units on a 100-unit insulin syringe. Moderate dose (100 mcg) is 10 units. Aggressive (200 mcg) is 20 units. With a 1 mg vial in 2 mL, concentrations halve; double your unit counts.
NPY degrades fast. Plasma half-life is 20 to 25 minutes because DPP-IV clips the N-terminal Tyr-Pro dipeptide almost immediately. Reconstitute fresh, store at 2 to 8 degrees Celsius, use within 14 days, and minimize needle punctures through the stopper. Every freeze-thaw cycle accelerates degradation.
The access situation is unusual. NPY doesn't appear on the gray market at all. Lab-grade material, sold only as a reagent for research, runs $337 to $537 per milligram. A valid CoA shows HPLC purity at or above 95% and mass spec confirming MW 4272.7 Da.
Cycling Protocol
Cycling is recommended due to potential receptor desensitization with chronic Y1/Y5 activation. Rodent studies show tachyphylaxis to orexigenic effects after sustained central infusion. Off-periods allow receptor resensitization. Protocols are extrapolated from animal data; no established human cycling guidelines exist.
Rodent studies demonstrate tachyphylaxis to NPY orexigenic effects after sustained central infusion, consistent with Y1/Y5 receptor downregulation and uncoupling from Gi/Go signaling. The 4-week on / 4-week off cycle in peptides.ts is extrapolated from animal data; no human cycling guidelines exist. Off-periods allow Y1/Y5 receptor resensitization.
- Reduced appetite stimulation response with continued dosing (primary desensitization signal)
- Attenuated anxiolytic effect over successive administrations
- Loss of vasoconstrictor response at previously effective doses
Or use the universal Peptide Calculator for any peptide.
Neuropeptide Y (NPY) Protocols by Goal
Expected: Dose-dependent reduction in anxiety symptoms (BAI); MADRS score improvement in MDD at 24h. Efficacy at 48h+ not established: repeated dosing likely required.
Monitor: Monitor blood pressure and heart rate after each dose. Transient bradycardia observed in one participant at 2.8 mg in NCT01533519. Monitor body weight with repeated dosing.
How to Use Neuropeptide Y (NPY)
- 1Step 1
Reconstitute the lyophilized NPY powder with bacteriostatic water using sterile technique. For a 2 mg vial, add 2 mL of bacteriostatic water to get 1000 mcg/mL. Gently swirl the vial. Do not shake.
- 2Let the solution reach room temperature before injection
NPY is sensitive to proteolytic degradation, so minimize time at higher temperatures.
- 3Draw your dose using an insulin syringe (29 to 31 gauge)
At 1000 mcg/mL concentration: 50 mcg = 5 units, 100 mcg = 10 units, 200 mcg = 20 units on a standard 100-unit insulin syringe.
- 4Step 4
Inject subcutaneously into the abdominal area or upper thigh. Rotate injection sites each time to avoid lipodystrophy.
- 5Step 5
Administer on an empty stomach or 30 minutes before a meal if appetite-related peripheral effects are being tracked.
- 6Check blood pressure before and 30 minutes after each dose
Monitor heart rate during and 60 minutes after the first administration.
- 7Store reconstituted NPY at 2 to 8 degrees Celsius
Use within 14 days. Minimize needle punctures through the vial stopper to reduce peptide degradation.
- 8Step 8
Document dose, timing, injection site, and any blood pressure or heart rate readings for each administration.
Alternative Routes
4.6–9.6 mg per dose (vs. 50–200 mcg SC listed in peptides.ts: see FLAG P0)
Requires specialized olfactory-targeted delivery device (not a standard pump nasal spray). Bypasses BBB via olfactory nerve pathway to deliver NPY directly to hypothalamus and limbic system. Custom OptiNose-type device used in clinical trials. No consumer equivalent available.
No validated human dose; 50–200 mcg listed in peptides.ts extrapolated from animal data (see FLAG P0)
NPY does not cross the BBB after SC injection in clinically relevant quantities. SC cannot replicate appetite stimulation or anxiolytic effects from intranasal trials. Only peripheral Y1-mediated vasoconstriction effects are observable via this route.
Animal models: 1–20 nmol direct brain infusion (basis of most orexigenic feeding data)
ICV infusion is the primary route behind essentially all appetite stimulation and weight gain data in rodent models. These effects are NOT translatable to any peripheral administration route in humans. Critical context for interpreting orexigenic benefit claims.
Neuropeptide Y (NPY) Stacking Protocols
Works With
Ghrelin stimulates NPY release from arcuate nucleus neurons: both operate on the same orexigenic pathway (ARC → PVN). Mechanistic synergy for appetite stimulation. No human combination data exists; theoretical only.
Both exert anxiolytic effects via distinct mechanisms: NPY via Y1 receptor CRF suppression, Selank via GABA-A/serotonin modulation. Theoretical complementary anxiolytic stack. No human combination data.
Avoid
Direct pharmacological opposition: GLP-1 agonists suppress NPY/AgRP neurons in the arcuate nucleus, counteracting any orexigenic intent of NPY administration
Do not combineNPY potentiates norepinephrine-mediated vasoconstriction via postjunctional Y1 receptors on vascular smooth muscle; additive hypertensive and cardiovascular risk
Do not combineNPY-mediated vasoconstriction may oppose therapeutic antihypertensive effects; reduced drug efficacy and unpredictable blood pressure response
Leptin suppresses NPY/AgRP neurons: exogenous leptin directly antagonizes NPY orexigenic signaling; opposing effects on appetite and energy balance
Estimated Cost
Neuropeptide Y (NPY) Side Effects
The most serious safety concern is cardiovascular. NPY is co-released with norepinephrine from sympathetic nerve terminals and potentiates vasoconstriction through Y1 receptors on vascular smooth muscle. Peripheral administration can raise blood pressure. Anyone with uncontrolled hypertension or cardiovascular disease should not use this compound. Blood pressure checks before and 30 minutes after every dose are a baseline safety requirement. The NCT01533519 trial flagged transient bradycardia in one participant at 2.8 mg intranasal, adding cardiac rhythm to the monitoring list.
Hyperphagia is the second concern, though context matters. The appetite-stimulating effects documented in rodent models used intracerebroventricular infusion, not peripheral routes. Subcutaneous NPY does not cross the blood-brain barrier in clinically relevant quantities, so orexigenic effects from SC injection are unlikely. If using intranasal delivery (the only route with human CNS data), unintended appetite stimulation and weight gain become plausible risks. Weekly body weight tracking is appropriate with repeated intranasal dosing.
Chronic central NPY infusion in rodents produced sustained hyperphagia, increased adiposity, and metabolic shifts favoring fat storage. These effects are route-specific and have not been confirmed through any peripheral administration method in humans. Still, the animal data warrants caution around repeated high-dose intranasal protocols.
Sedation and reduced locomotor activity appeared in some rodent studies following central administration. Hypothermia was reported after intracerebroventricular injection in certain models. These observations may or may not translate to intranasal delivery in humans at milligram-range doses.
NPY modulates multiple neurotransmitter systems, including GABA, glutamate, and norepinephrine. Off-target neurological effects are possible at supratherapeutic concentrations. Gastrointestinal effects, specifically delayed gastric emptying and altered intestinal motility, are documented in animal models.
Drug interactions deserve specific attention. Sympathomimetics (ephedrine, phenylephrine) create additive vasoconstriction risk. Beta-blockers and antihypertensives may lose efficacy because NPY opposes their mechanism. Benzodiazepines could produce additive sedation with central NPY effects. GLP-1 receptor agonists and leptin directly antagonize NPY's orexigenic pathways.
Contraindications: uncontrolled hypertension or cardiovascular disease, obesity or metabolic syndrome (where appetite stimulation is counterproductive), active eating disorders, pregnancy or breastfeeding (no safety data), and known hypersensitivity to NPY or formulation excipients.
When to stop: systemic blood pressure elevation above 140 mmHg, sustained bradycardia below 50 bpm, any new arrhythmia on ECG, or unintended weight gain outside research parameters. These are hard stop criteria, not suggestions.
Common Issues & Solutions
No CNS response (appetite or anxiety) from SC injection: Expected. NPY does not cross the blood-brain barrier in clinically relevant quantities after peripheral administration. All CNS endpoints require intranasal delivery via olfactory nerve pathway.
Peptide degradation: NPY has a ~20–25 min plasma half-life due to rapid DPP-IV and peptidase cleavage of the N-terminal Tyr-Pro dipeptide. Reconstitute fresh, keep at 2–8°C, use within 14 days, minimize freeze-thaw cycles.
Unexpected blood pressure elevation: Vasoconstriction via Y1 receptors on vascular smooth muscle is an expected peripheral NPY effect. Discontinue and monitor; check for interaction with any sympathomimetic or cardiovascular medications.
Diminishing appetite or anxiolytic response over time: Consistent with Y1/Y5 receptor desensitization (tachyphylaxis) documented in rodent models after sustained central infusion. Implement 4-week off cycling protocol.
Access and cost barrier: NPY is sold only as a lab reagent for research, at ~$337–537/mg. It is absent from the gray market. Verify authenticity via CoA with HPLC purity ≥95% and mass spec confirmation of MW 4272.7 Da.
Ask AI about this page
Ask AI for a second opinion on Neuropeptide Y (NPY) dosing and side effects
Contraindications
- Uncontrolled hypertension or cardiovascular disease due to vasoconstrictor effects
- Obesity or metabolic syndrome where appetite stimulation is contraindicated
- Active eating disorders where orexigenic signaling could be harmful
- Pregnancy or breastfeeding due to lack of safety data
- Known hypersensitivity to NPY or any excipients in the formulation
Drug Interactions
- Sympathomimetic agents (additive vasoconstrictor and hypertensive effects)
- Beta-blockers and antihypertensives (NPY-mediated vasoconstriction may oppose therapeutic effects)
- Anxiolytic medications including benzodiazepines (potential additive sedation with central NPY effects)
- Leptin or leptin analogs (antagonistic effects on appetite regulation pathways)
- GLP-1 receptor agonists (opposing effects on food intake and energy balance)
- GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide)
Product Quality
NPY does not appear in the gray-market research peptide market. It is sold only as a lab reagent for research, at $337–537/mg with lab-grade CoA. No third-party purity testing benchmarks exist for consumer-grade sourcing, and no 503B compounding pathway allows legal US pharmacy sourcing.
- NPY is sold only as a lab reagent for research; versions from unverified research peptide websites carry no identity guarantee
- A valid certificate of analysis (CoA) shows HPLC purity ≥95% and mass spectrometry confirmation of MW 4272.7 Da (human NPY, 36 aa)
- Use immediately after reconstitution: NPY degrades rapidly due to DPP-IV cleavage of the N-terminal Tyr-Pro dipeptide; minimize freeze-thaw cycles
- No known counterfeit NPY market (too expensive and niche), but verify sequence via CoA: authentic human NPY is a 36-aa C-terminally amidated peptide (MW 4272.7 Da)
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Blood pressure (systolic/diastolic) | Before and 30 min post-dose each administration | Systolic <140 mmHg; discontinue if persistently elevated above baseline |
| Heart rate / ECG | During and 60 min after first administration | HR >50 bpm; no new arrhythmia on ECG |
| Body weight and caloric intake log | Weekly with repeated dosing | Within intended research parameters |
Y1 receptor-mediated vasoconstriction on vascular smooth muscle is a primary peripheral NPY effect
Bradycardia observed in one NCT01533519 participant at 2.8 mg intranasal; cardiac co-modulation via sympathetic NPY/norepinephrine co-release
Unintended hyperphagia and adiposity gain documented with repeated central dosing in animal models; relevant tracking for any orexigenic research protocol
Neuropeptide Y (NPY) Before and After
Rapid onset of orexigenic signaling following central administration in animal models; peripheral vasoconstrictor effects observed within minutes
Sustained hyperphagia and increased caloric intake with repeated central dosing; measurable changes in anxiety-related behavior in rodent models
Chronic central infusion produces significant weight gain, increased adiposity, and metabolic shifts toward lipogenesis in animal studies
Potential tachyphylaxis to orexigenic effects; receptor desensitization may attenuate feeding response; bone density changes detectable in long-term Y2 receptor studies
What to Expect
Acute (0 to 30 minutes): Peripheral vasoconstriction and potential heart rate changes appear within minutes of subcutaneous injection. Plasma NPY clears in roughly 20 to 25 minutes via DPP-IV degradation. Intranasal delivery through an olfactory-targeted device reaches brain tissue within about 15 minutes (ACS Pharm Transl Sci 2025)[2]. Transient blood pressure elevation and injection site reactions are the main acute side effects. One case of bradycardia was flagged at 2.8 mg intranasal in the PTSD trial.
Day 1 to 7: Intranasal-only data here. The MDD trial showed MADRS depression score improvement at 5 hours (Cohen's d = 0.61) and 24 hours (d = 0.67) after a single 6.8 mg dose. By 48 hours, the effect was gone. That rapid falloff suggests repeated dosing would be needed for sustained benefit, but no multi-dose human schedule has been validated. Subcutaneous dosing during this window would only produce peripheral vasoconstrictor effects; no CNS anxiolytic or orexigenic response is expected.
2 to 4 weeks: Everything in this window comes from rodent ICV models, not humans. Sustained central infusion in rodents produces hyperphagia, body weight gain, increased adiposity, and metabolic shifts toward lipogenesis. Tachyphylaxis to the orexigenic effect begins during this period. None of this data translates to peripheral human dosing.
4 to 8 weeks: Y1/Y5 receptor desensitization is documented in rodent models with continued central dosing. The appetite-stimulating response attenuates. Bone density changes become detectable in long-term Y2 receptor studies in animals. Off-cycling (4 weeks on, 4 weeks off) is recommended to allow receptor resensitization, though this schedule is extrapolated from animal data with no human validation.
Detailed Timeline: Science vs Community
Vasoconstriction and potential heart rate changes within minutes of administration; plasma NPY cleared within ~20–25 min by DPP-IV. Intranasal: brain uptake begins within ~15 min (ACS Pharm Transl Sci 2025, PMID 40242586).
No documented community reports
Intranasal: significant anxiolytic effect within hours; MDD trial showed MADRS improvement at 5h (d=0.61) and 24h (d=0.67) but not 48h: repeated dosing likely needed. SC route: no CNS effects expected.
No documented community reports
Sustained hyperphagia and body weight gain with repeated central infusion in rodents; significant adiposity increase favoring lipogenesis. No equivalent human data for this duration.
No documented community reports
Documented Y1/Y5 receptor desensitization in rodent models; attenuated feeding response. Long-term Y2 receptor signaling influences bone homeostasis: osteoblast changes detectable in long-term animal studies.
No documented community reports
Pharmacokinetics
Source: Plasma elimination studies; NPY has a half-life of approximately 20-25 minutes in circulation due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and other peptidases
Pharmacokinetics: Active Dose Over Time
t½ = ~20-30 minutes (plasma)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Neuropeptide Y (NPY) Legal?
NPY carries a "research-only" regulatory status. It has no FDA approval for any therapeutic indication. It is not listed on the FDA 503A or 503B bulks lists, which means US compounding pharmacies have no legal pathway to produce NPY preparations for patient use.
NPY is not currently sold on the gray market. It is sold only as a lab reagent for research, at research-grade pricing. WADA status should be verified by any athlete, though NPY's impracticality as a performance compound makes competitive testing unlikely.
Two Investigational New Drug (IND) applications have supported clinical trials in the US (NCT01533519 for PTSD, a separate MDD trial), but these were conducted under strict FDA IND protocols with specialized delivery devices. No consumer-accessible intranasal delivery system replicates the olfactory-targeted devices used in those studies.
All information on this page is for educational and research reference purposes only. Nothing here constitutes medical advice, a treatment recommendation, or encouragement to use any compound outside of approved clinical or research settings.
Evidence grade: Phase 2 trial (Peptide Evidence Gap, October 2026)
Who Should Consider Neuropeptide Y (NPY)
- Researchers studying appetite regulation and energy homeostasis
- Neuroscience investigators examining stress resilience and anxiety pathways
- Cardiovascular researchers exploring sympathetic vasoconstriction mechanisms
- Endocrinologists studying hypothalamic peptide signaling networks
- Bone biology researchers investigating Y-receptor-mediated osteogenesis
Related Peptides
What Changed for Neuropeptide Y (NPY)
Peptide Schedule Research TeamReviewed Apr 8, 20268 Citations
References
- [1]Plasma neuropeptide-Y concentrations in humans exposed to military survival training (Morgan et al., Biol Psychiatry 2000) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Intranasal Application of Peptides Modulating the Neuropeptide Y System (ACS Pharmacol Transl Sci 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Neuropeptide Y and its role in CNS disease and repair (opens in a new tab)PubMed 23022456Review
- Neuropeptide Y: a stressful review (opens in a new tab)PubMed 26441327Review
- The role of neuropeptide Y in cardiovascular regulation (opens in a new tab)PubMed 2053188PubMed
- Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome (opens in a new tab)PubMed 17603492PubMed
- PTSD (NCT01533519) (opens in a new tab)Clinical Trial
- PMC5795352 (PMC5795352) (opens in a new tab)PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Neuropeptide Y (NPY)?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 15. Community mentions on Reddit: <15 threads: academic/nootropic interest.
14,200 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Minimal search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.